• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Modular Medical Announces Results from a Successful GLP-1 Proof of Concept Study

    11/7/24 8:00:00 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care
    Get the next $MODD alert in real time by email

    -Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery

    - Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone

    -Findings suggest that pump delivery may be a viable approach to achieve GLP-1 weight and blood glucose benefits that are comparable with current treatment standards, either as initial treatment or for maintenance, while bringing personalized dosing flexibility

    SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, announced successful results from its pre-clinical GLP-1 proof of concept study.

    "We are excited by the results of this pre-clinical, proof of concept study in a standard obese mouse model," stated Dr. David Maggs, M.D., medical advisor for this study. "We used a rapid-acting GLP-1 with a short half-life delivered by pump at a continuous basal rate, with several treatment arms adding a moderate additional bolus, just once a day, at the start of the feeding cycle. At the highest basal-bolus dose, we saw a 17.1% weight loss at 28 days compared to 13.7% with basal alone at the same dose, despite the short half-life of bolus GLP-1. We believe this profound effect strongly suggests that a pump delivered basal-bolus GLP-1 could bring weight and glucose benefits similar to or beyond those observed with long-acting and basal-only GLP-1 treatment modalities. A pump-delivered GLP-1 may also offer dosing flexibility for those patients sensitive to GI issues common among currently available GLP-1s. All dosing variations of the rapid-acting GLP-1 outperformed semaglutide in controlling blood glucose excursion after a standard glucose challenge, with the basal-bolus combinations performing the best."

    As expected, none of the rapid acting GLP-1 arms matched the overall weight loss effect of the semaglutide arm. Notably, however, the semaglutide treated mice lost 8% of their body weight in the first two days of treatment as food and water intake was almost entirely absent. The rapid acting GLP-1 pump-treated mice had a much smoother initiation of treatment, as measured by body weight and food and water intake.

    "With these encouraging results, we are now planning to take this concept of a synergistic basal-bolus GLP-1 combination into a human trial using our MODD1 device. We are considering both existing fast acting GLP-1s and other peptides for this trial, as we see this as a platform technology that could be used for more personalized titration for both non-responder or non-adherent patients experiencing GI and other issues with long acting GLP-1s, as well as for other specialty applications in metabolic therapies. This type of application is well suited for our MODD1 pump, given its quick training time, simple interface, high accuracy at low flow rates, reusable low-cost electronics, and a prefill-capable 3mL reservoir," stated Jeb Besser, CEO of Modular Medical.

    While the full details of the study will be presented in subsequent communications, the topline data for weight loss in the diet-induced obese mouse model used is as set forth below.

    The study was conducted across 5-arms. Dosing and corresponding body weight loss at 28 days were:

    Arm 1: Vehicle / no active drug 4.69%

    Arm 2: 30 mcg basal with 20 mcg bolus once daily 13.82%

    Arm 3: 50 mcg basal only 13.66%

    Arm 4: 50 mcg basal with 20 mcg bolus once daily 17.09%

    Arm 5: Semaglutide bolus daily 24.9% (8% in first 2 days)

    Forward-Looking Statements

    This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release. including but not limited to, whether the Company performs future GLP-1 trials, the potential for ongoing preclinical or clinical trials and results thereof; FDA or other regulatory findings and approvals; potential market opportunities; and the occurrence of future events or circumstances, successful development of Modular Medical's proprietary technologies, whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products, whether Modular Medical can successfully manufacture its products at high volumes, general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.

    About Modular Medical

    Modular Medical, Inc. (NASDAQ:MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."

    Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

    All trademarks mentioned herein are the property of their respective owners.

    CONTACT:
    Jeb Besser
    Chief Executive Officer
    Modular Medical, Inc.
    +1 (617) 399-1741
    [email protected]

    SOURCE: Modular Medical, Inc.



    View the original press release on accesswire.com

    Get the next $MODD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MODD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MODD
    SEC Filings

    View All

    Modular Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Modular Medical, Inc. (0001074871) (Filer)

    9/23/25 8:30:42 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Modular Medical Inc.

    EFFECT - Modular Medical, Inc. (0001074871) (Filer)

    8/20/25 12:15:02 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form POS AM filed by Modular Medical Inc.

    POS AM - Modular Medical, Inc. (0001074871) (Filer)

    8/13/25 5:29:22 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Manchester Management Co Llc bought $1,299,997 worth of shares (677,082 units at $1.92) (SEC Form 4)

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    3/24/25 9:34:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Director by Deputization Manchester Management Co Llc bought $35,236 worth of shares (21,000 units at $1.68) (SEC Form 4)

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    12/4/24 6:05:34 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Director by Deputization Manchester Management Co Llc bought $168,950 worth of shares (100,000 units at $1.69) (SEC Form 4)

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    11/29/24 10:00:09 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Goldberg Jeff D

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    10/3/25 6:21:17 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Vos Ellen O'Connor

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    10/2/25 8:34:55 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Sheibley Philip Brent

    4 - Modular Medical, Inc. (0001074871) (Issuer)

    10/2/25 8:33:46 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Modular Medical Announces Licensing and Partnership Agreement With Nudge BG

    -Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements-Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 19, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, announced a licensing and partnership agreement with Nudge BG."We are very excited to partner with Modular Medical to bring the next g

    12/19/24 4:01:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Announces Conference Call to Provide Business Update

    SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced it will hold a conference call and webcast on Thursday, December 5, 2024, at 10:00 a.m. Eastern Time to provide a business update.Conference Call and Webcast InformationDate: December 5, 2024Time: 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time)Conference Call Number: 1-888-506-0062International Call Number: +1-973-528-0011Passcode: 494842Webcast: CLICK HEREFor those unable to

    12/3/24 8:00:00 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Announces Pricing of $8.2 Million Public Offering

    SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has priced an underwritten public offering (the "offering") of 5,450,573 shares of its common stock. The offering was led by existing institutional investors, including Manchester Explorer, L.P., which is the largest shareholder of the Company and is managed by Jeb Besser, Modular Medical's Chief Executive Officer. The shares of common stock are being sold at a price t

    11/21/24 9:15:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Leadership Updates

    Live Leadership Updates

    View All

    Modular Medical Announces Addition to the Russell Microcap(R) Index

    SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalizatio

    6/3/24 8:00:00 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Announces Diabetes Industry Veteran Duane DeSisto Will Join the Board of Directors

    SAN DIEGO, CA / ACCESSWIRE / July 6, 2023 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced the appointment of medical device industry leader Duane DeSisto to its board of directors. Mr. DeSisto was previously President, CEO and Director of Insulet Corporation, developers of the groundbreaking OmniPod Insulin Management System, before retiring in 2014."Duane brings more than 25 years of experience in the medical device industry and is a visionary business leader credited with the launch and transformatio

    7/6/23 8:30:00 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Appoints Kevin Schmid as Chief Operating Officer

    Schmid brings 40 years of experience in medical devices for drug delivery and diabetes management and a background in high-volume manufacturingSAN DIEGO, CA / ACCESSWIRE / July 26, 2022 / Modular Medical, Inc. (the "Company" or "Modular Medical")(NASDAQ:MODD) today announced that it has appointed industry veteran Kevin Schmid as its Chief Operating Officer. Mr. Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the Omnipod Diabete

    7/26/22 8:15:00 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Financials

    Live finance-specific insights

    View All

    Modular Medical Announces Conference Call to Provide Business Update

    SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced it will hold a conference call and webcast on Thursday, December 5, 2024, at 10:00 a.m. Eastern Time to provide a business update.Conference Call and Webcast InformationDate: December 5, 2024Time: 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time)Conference Call Number: 1-888-506-0062International Call Number: +1-973-528-0011Passcode: 494842Webcast: CLICK HEREFor those unable to

    12/3/24 8:00:00 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Announces Conference Call to Discuss FDA Clearance of the MODD1 Insulin Pump

    SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U. S. Food and Drug Administration ("FDA") clearance of its MODD1 pump, as well as next steps and milestones.Conference Call and Webcast InformationDate: September 5, 2024Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Conference Call Number: 1-88

    9/4/24 6:57:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Modular Medical Announces FDA Clearance of the MODD1 Insulin Pump

    MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetesDesigned to be simpler and more affordable to expand access to diabetes technology for previously underserved communitiesCommercial availability expected in early 2025 SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States. With its comme

    9/4/24 4:30:00 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $MODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Modular Medical Inc.

    SC 13G - Modular Medical, Inc. (0001074871) (Subject)

    3/1/24 3:48:41 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Modular Medical Inc. (Amendment)

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    2/21/24 5:20:18 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care